Bavarian Nordic CEO Says Likely To Sell Imvamune Priority Review Voucher
Danish group believes its smallpox vaccine will get approved, generate a transferable priority review voucher, and replace the current US-licensed replicating smallpox vaccine ACAM2000.
You may also be interested in...
Keeping Track: Two Goal Date Extensions, Another Herceptin Biosimilar Approval, And A BLA Withdrawal
The latest drug development news and highlights from our US FDA Performance Tracker.
US FDA’s Biologics Center Faces Exciting 2019 After Quiet Year For Novel Approvals
CBER’s novel biologic approvals in 2018 were few, long, and with a low level of innovation. But the center’s work to build regulatory framework for emerging technologies is setting the stage for a different story in 2019.
Bavarian Nordic CEO Hopes Chordoma Vaccine Can Be Launched By Mid-2020
Danish vaccine specialist's BN-Brachyury has been granted orphan drug designation by the FDA for treating chordoma.